SGLT 2 Inhibitors | Short Notes | Diabetes Pharmacology

SGLT-2 Inhibitors (Gliflozins) | Mechanism, Uses, Benefits & Adverse Effects Learn SGLT-2 Inhibitors (Gliflozins) in a clear, exam-oriented format. This video covers the mechanism of action, pharmacological effects, adverse effects, clinical uses, and the important cardiovascular and renal benefits that have made SGLT-2 inhibitors one of the most significant drug classes in modern diabetes management. SGLT-2 inhibitors lower blood glucose by increasing urinary glucose excretion through inhibition of the sodium-glucose cotransporter-2 in the proximal renal tubule. Unlike many other antidiabetic drugs, their glucose-lowering action is independent of insulin secretion, resulting in a low risk of hypoglycemia when used alone. This video discusses key drugs including Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin, and Remogliflozin, along with their mechanism, metabolic effects, adverse effects, and expanding role beyond diabetes. Topics Covered ✅ Introduction to SGLT-2 Inhibitors (Gliflozins) ✅ Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin & Remogliflozin ✅ Mechanism of Action of SGLT-2 Inhibitors ✅ Reduction in Renal Glucose Reabsorption ✅ Glycosuria and Glucose Lowering ✅ Insulin-Independent Action ✅ Mild Weight Loss ✅ Blood Pressure Reduction ✅ Genital Fungal Infections ✅ Urinary Tract Infections (UTIs) ✅ Polyuria and Osmotic Diuresis ✅ Hypotension ✅ Euglycemic Diabetic Ketoacidosis (DKA) ✅ Canagliflozin and Amputation Risk ✅ Type 2 Diabetes Mellitus ✅ Combination Therapy in Diabetes ✅ Heart Failure Benefits ✅ Chronic Kidney Disease (CKD) Protection ✅ Cardiovascular Protection ✅ Weight Reduction in Obesity ✅ Major Adverse Cardiovascular Events (MACE) ✅ Examination-Oriented Summary Key Learning Points • Block SGLT-2 → reduce glucose reabsorption → increase urinary glucose excretion • Lower blood glucose independent of insulin secretion • Promote modest weight loss and blood pressure reduction • Reduce heart failure hospitalization and mortality • Slow progression of diabetic and non-diabetic chronic kidney disease • Provide cardiovascular and renal protection beyond glycemic control • Important adverse effects include genital fungal infections, UTIs, hypotension, and euglycemic DKA This video is useful for: MBBS Students BDS Students Nursing Students Pharmacy Students GPAT Aspirants Pharmacology Postgraduates Medical Entrance & Viva Preparation Healthcare Professionals seeking a quick revision #SGLT2Inhibitors #Gliflozins #Dapagliflozin #Empagliflozin #Canagliflozin #Ertugliflozin #Remogliflozin #DiabetesMellitus #Type2Diabetes #Pharmacology #MedicalEducation #MBBS #Pharmacy #Nursing #HeartFailure #CKD #CardiovascularProtection #DiabetesDrugs #NEETPG #FMGE #INICET #PharmacologyEssentialsDotCom